PROTAC technology for prostate cancer treatment

PROTAC technology for prostate cancer treatment

Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing cancer cell dissemination to distant sites,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei
Format:	Article
Language:	English
Published:	Compuscript Ltd 2025-01-01
Series:	Acta Materia Medica
Online Access:	https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0075
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PROTAC-based therapeutics for targeting HPV oncoproteins in head and neck cancers
by: Nobendu Mukerjee, et al.
Published: (2025-12-01)

Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01)

Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
by: Camilla Ruffilli, et al.
Published: (2025-01-01)

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors
by: Ezequiel J. Tolosa, et al.
Published: (2024-12-01)

PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01)

A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
by: Linghong Huang, et al.
Published: (2025-04-01)

Fortifying the Treatment of Prostate Cancer with Physical Activity
by: Colin E. Champ, et al.
Published: (2016-01-01)

Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
by: Maurizio Capuozzo, et al.
Published: (2024-05-01)

Photodynamic therapy for the precise treatment of localized prostate cancer
by: Youcheng Xu, et al.
Published: (2025-02-01)

Prostate Cancer
by: Scott Eggener
Published: (2011-01-01)

eHealth, digital information and technology use of men with prostate cancer
by: Stuart R Jackson, et al.
Published: (2025-01-01)

New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01)

Focal Treatment of Prostate Cancer with Vascular-Targeted Photodynamic Therapy
by: Scott E. Eggener, et al.
Published: (2008-01-01)

Treatment Planning Strategies for Interstitial Ultrasound Ablation of Prostate Cancer
by: Pragya Gupta, et al.
Published: (2024-01-01)

Rubin H. Flocks and Colloidal Gold Treatments for Prostate Cancer
by: Henry M. Rosevear, et al.
Published: (2011-01-01)

Outcomes of Surgical Treatment of Multiple Primary Colorectal and Prostate Cancer
by: I. S. Ignatov, et al.
Published: (2025-02-01)

Cholestatic Jaundice as a Paraneoplastic Manifestation of Prostate Cancer
by: Tomomi Kuramoto, et al.
Published: (2013-01-01)

Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia
by: Wei Jin, et al.
Published: (2020-01-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence
by: Youcef Derbal
Published: (2025-01-01)

Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer
by: Sakshi Sikka, et al.
Published: (2012-01-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
by: Kuang Youlin, et al.
Published: (2012-01-01)

Prostate Artery Embolization in the Setting of Prostate Cancer: Review and Opinion
by: Nainesh Parikh MD, MBA, et al.
Published: (2025-01-01)

Mesenchymal stromal cell exosomes for drug delivery of prostate cancer treatments: a review
by: Chengran Wang, et al.
Published: (2025-01-01)

Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance
by: Caihong Li, et al.
Published: (2025-02-01)

Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer
by: Alacia M. Voth, et al.
Published: (2017-05-01)

Mouse Models of Prostate Cancer
by: Kenneth C. Valkenburg, et al.
Published: (2011-01-01)

Modalities for Imaging of Prostate Cancer
by: A. H. Hou, et al.
Published: (2009-01-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Solitary Fibrous Tumor of the Prostate Which Was Initially Misdiagnosed as Prostate Cancer
by: Soma Osamu, et al.
Published: (2017-01-01)

Incidental Prostate Cancer in Transurethral Resection of the Prostate Specimens in the Modern Era
by: Brandon Otto, et al.
Published: (2014-01-01)

Therapy of Prostate Cancer by Nanoyam Polysaccharide
by: Cheng Peng, et al.
Published: (2019-01-01)

GILT stabilizes cofilin to promote the metastasis of prostate cancer
by: Dunsheng Han, et al.
Published: (2025-01-01)

Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer
by: Yuxuan Chen, et al.
Published: (2025-01-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
by: Zh. R. Cherkasova, et al.
Published: (2023-03-01)

Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer
by: Feng Qi, et al.
Published: (2025-01-01)

Correction: Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer
by: Minmin Lan, et al.
Published: (2025-02-01)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01)

An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
by: Yi Wu, et al.
Published: (2025-01-01)